Press Releases
Partnership for Safe Medicines Applauds FDA Reform Bill
WASHINGTON, DC (May 1, 2008) – The Partnership for Safe Medicines, a group of organizations and individuals dedicated to protect consumers from counterfeit medicines, issued the following statement regarding today's hearing on Food and Drug Administration (FDA) Globalization Act of 2008 held by the House Committee on Energy and Commerce’s Subcommittee on Health.
Dubbed by supporters as the “FDA reform bill,” the Partnership for Safe Medicines thanks Rep. John Dingell and other members of the Committee for moving this legislation forward. Recent events have demonstrated that reform is necessary, and overdue.
Partnership for Safe Medicines Supports Change in Foreign Inspection Process
WASHINGTON, DC (April 29, 2008) – The Partnership for Safe Medicines, a group of organizations and individuals dedicated to protect consumers from counterfeit medicines, issued the following statement regarding today's hearing on the examination of the events leading up to the distribution of contaminated heparin and Chinese plant inspections held by the House Committee on Energy and Commerce’s Subcommittee on Oversight and Investigations.
The Partnership for Safe Medicines applauds the Subcommittee for recognizing the importance and urgency of eliminating contaminated drugs. Unfortunately, this recent case of heparin contamination is just one example of the increasingly global problem of counterfeit drugs sold to an unsuspecting public.
Consumer Protection Group Issues Statement About FDA's Ability to Enforce Safety Regulations
WASHINGTON, DC (April 24, 2008) – The Partnership for Safe Medicines, a group of organizations and individuals dedicated to protect consumers from counterfeit medicines, issued the following statement regarding today's hearing on the Food and Drug Administration’s (FDA) ability to enforce safety regulations held by the Senate Committee on Health, Education, Labor, and Pensions.
The Partnership for Safe Medicines applauds the Committee for recognizing that the FDA’s ability to safeguard America’s food and drug supplies is being compromised by numerous challenges and obstacles. Unfortunately, this recent case of heparin contamination is just one example of the increasingly global problem of counterfeit drugs sold to an unsuspecting public.
Partnership for Safe Medicines Issues Statement About FDA Foreign Drug Inspection Program
WASHINGTON, DC (April 22, 2008) – The Partnership for Safe Medicines, a group of organizations and individuals dedicated to protect consumers from counterfeit medicines, issued the following statement regarding today's hearing on the Food and Drug Administration’s (FDA) efforts to inspect foreign drug plants making products for the U.S. market held by the House Committee on Energy and Commerce’s Subcommittee on Oversight and Investigations.
The Partnership for Safe Medicines echoes the concerns expressed by Congressmen Dingell, Barton, Stupak and Shimkus about the state of the FDA’s foreign drug inspection program. There is a strong need for strict, rigorous regulatory oversight of imported drugs to keep situations such as the recent heparin contamination from repeating in the future. However, progress in the fight against counterfeit and contaminated medications is unforeseeable unless we give the FDA all the tools it truly needs to fix the problems.
Partnership for Safe Medicines Echoes Concerns Raised in House Subcommittee Hearing
WASHINGTON, D.C. (February 27, 2008) – The Partnership for Safe Medicines, a group of organizations and individuals dedicated to protect consumers from counterfeit medicines, issued the following statement regarding today's hearing on drug safety held by House Appropriation's Committee's Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies.
The Partnership for Safe Medicines echoes several of the concerns expressed by Congresswoman DeLauro about counterfeit pharmaceuticals and the security of the U.S. drug distribution system. Recent events serve as a reminder that our country is not completely protected from counterfeit drugs. It is paramount to remember medications are specialized goods, not commodities, and need to be used with care and understanding. To provide the U.S. public with the best care, we need to develop stringent pharmaceutical quality assurance programs and develop a drug distribution system that is without compromise.
This Subcommittee hearing address key issues core to our mission – to protect consumers from contraband and counterfeit medicines. While Congress and FDA work to improve the distribution system, the Partnership encourages consumers to learn how they can take steps to protect themselves from contraband and potentially counterfeit medicines.
# # #
About the Partnerships for Safe Medicines
The Partnership for Safe Medicines is a group of organizations and individuals that have policies, procedures, or programs to protect consumers from counterfeit or contraband medicines. For more information, please visit http://www.safemedicines.org